Ji Xing Acquires Tachycardia Treatment in $127.5 Million Deal

Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma (NSDQ: MIST) in a $127.5 million agreement. Ji Xing's backer, RTW Investments, a New York company focused on innovative medicines for China , will make a $15 million upfront payment to Milestone and invest $5 million in the company. Ji Xing will be responsible for up to $107.5 million in milestone payments. Milestone is conducting a US Phase III trial of the candidate, etripamil, a nasal treatment for paroxysmal supraventricular tachycardia. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.